These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 25332171)

  • 1. An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapy.
    Rao VU; Pavlov A; Klearman M; Musselman D; Giles JT; Bathon JM; Sattar N; Lee JS
    Arthritis Rheumatol; 2015 Feb; 67(2):372-80. PubMed ID: 25332171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The efficacy and safety of tocilizumab combined with disease-modifying anti-rheumatoid drugs in the treatment of active rheumatoid arthritis: a multi-center, randomized, double-blinded, placebo-controlled trial].
    Shi Q; Zhao Y; Bao CD; Li XF; Huang F; Zhu P; Li ZG; Gu JR; Zhang ZY; Zhao DB; Zhao SL; Jiang QD; Tian J; Zhang FC
    Zhonghua Nei Ke Za Zhi; 2013 Apr; 52(4):323-9. PubMed ID: 23925361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular Safety of Tocilizumab Versus Etanercept in Rheumatoid Arthritis: A Randomized Controlled Trial.
    Giles JT; Sattar N; Gabriel S; Ridker PM; Gay S; Warne C; Musselman D; Brockwell L; Shittu E; Klearman M; Fleming TR
    Arthritis Rheumatol; 2020 Jan; 72(1):31-40. PubMed ID: 31469238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long-Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis.
    Charles-Schoeman C; DeMasi R; Valdez H; Soma K; Hwang LJ; Boy MG; Biswas P; McInnes IB
    Arthritis Rheumatol; 2019 Sep; 71(9):1450-1459. PubMed ID: 31385441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis.
    Gabay C; McInnes IB; Kavanaugh A; Tuckwell K; Klearman M; Pulley J; Sattar N
    Ann Rheum Dis; 2016 Oct; 75(10):1806-12. PubMed ID: 26613768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipids and Atherogenic Indices Fluctuation in Rheumatoid Arthritis Patients on Long-Term Tocilizumab Treatment.
    Cacciapaglia F; Anelli MG; Rinaldi A; Fornaro M; Lopalco G; Scioscia C; Lapadula G; Iannone F
    Mediators Inflamm; 2018; 2018():2453265. PubMed ID: 30405318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ROUTINE-a prospective, multicentre, non-interventional, observational study to evaluate the safety and effectiveness of intravenous tocilizumab for the treatment of active rheumatoid arthritis in daily practice in Germany.
    Iking-Konert C; von Hinüber U; Richter C; Schwenke H; Gürtler I; Kästner P; Klapperich B; Peters MA; Burmester GR
    Rheumatology (Oxford); 2016 Apr; 55(4):624-35. PubMed ID: 26515959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure.
    Genovese MC; Rubbert-Roth A; Smolen JS; Kremer J; Khraishi M; Gómez-Reino J; Sebba A; Pilson R; Williams S; Van Vollenhoven R
    J Rheumatol; 2013 Jun; 40(6):768-80. PubMed ID: 23457383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between lipid levels and major adverse cardiovascular events in rheumatoid arthritis compared to non-rheumatoid arthritis patients.
    Liao KP; Liu J; Lu B; Solomon DH; Kim SC
    Arthritis Rheumatol; 2015 May; 67(8):2004-10. PubMed ID: 25917955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.
    van Vollenhoven RF; Fleischmann R; Cohen S; Lee EB; García Meijide JA; Wagner S; Forejtova S; Zwillich SH; Gruben D; Koncz T; Wallenstein GV; Krishnaswami S; Bradley JD; Wilkinson B;
    N Engl J Med; 2012 Aug; 367(6):508-19. PubMed ID: 22873531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study.
    Yazici Y; Curtis JR; Ince A; Baraf H; Malamet RL; Teng LL; Kavanaugh A
    Ann Rheum Dis; 2012 Feb; 71(2):198-205. PubMed ID: 21949007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.
    Genovese MC; McKay JD; Nasonov EL; Mysler EF; da Silva NA; Alecock E; Woodworth T; Gomez-Reino JJ
    Arthritis Rheum; 2008 Oct; 58(10):2968-80. PubMed ID: 18821691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year.
    Kremer JM; Blanco R; Brzosko M; Burgos-Vargas R; Halland AM; Vernon E; Ambs P; Fleischmann R
    Arthritis Rheum; 2011 Mar; 63(3):609-21. PubMed ID: 21360490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Impact of Newer Biological Disease Modifying Anti-Rheumatic Drugs on Cardiovascular Risk Factors: A 12-Month Longitudinal Study in Rheumatoid Arthritis Patients Treated with Rituximab, Abatacept and Tociliziumab.
    Provan SA; Berg IJ; Hammer HB; Mathiessen A; Kvien TK; Semb AG
    PLoS One; 2015; 10(6):e0130709. PubMed ID: 26114946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants.
    Smolen JS; Aletaha D
    Arthritis Rheum; 2011 Jan; 63(1):43-52. PubMed ID: 21204103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Importance of methotrexate therapy concomitant with tocilizumab treatment in achieving better clinical outcomes for rheumatoid arthritis patients with high disease activity: an observational cohort study.
    Kojima T; Yabe Y; Kaneko A; Takahashi N; Funahashi K; Kato D; Hanabayashi M; Asai S; Hirabara S; Asai N; Hirano Y; Hayashi M; Miyake H; Kojima M; Ishiguro N
    Rheumatology (Oxford); 2015 Jan; 54(1):113-20. PubMed ID: 25102861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan.
    Koike T; Harigai M; Inokuma S; Ishiguro N; Ryu J; Takeuchi T; Takei S; Tanaka Y; Sano Y; Yaguramaki H; Yamanaka H
    J Rheumatol; 2014 Jan; 41(1):15-23. PubMed ID: 24187110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns of use and dosing of tocilizumab in the treatment of patients with rheumatoid arthritis in routine clinical practice: the ACT-LIFE study.
    Balsa A; Tovar Beltrán JV; Cáliz Cáliz R; Mateo Bernardo I; García-Vicuña R; Rodríguez-Gómez M; Belmonte Serrano MA; Marras C; Loza Cortina E; Pérez-Pampin E; Vila V
    Rheumatol Int; 2015 Sep; 35(9):1525-34. PubMed ID: 25773655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longterm Safety and Efficacy of Subcutaneous Tocilizumab Monotherapy: Results from the 2-year Open-label Extension of the MUSASHI Study.
    Ogata A; Amano K; Dobashi H; Inoo M; Ishii T; Kasama T; Kawai S; Kawakami A; Koike T; Miyahara H; Miyamoto T; Munakata Y; Murasawa A; Nishimoto N; Ogawa N; Ojima T; Sano H; Shi K; Shono E; Suematsu E; Takahashi H; Tanaka Y; Tsukamoto H; Nomura A;
    J Rheumatol; 2015 May; 42(5):799-809. PubMed ID: 25834203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of disease activity with acute exacerbation of interstitial lung disease during tocilizumab treatment in patients with rheumatoid arthritis: a retrospective, case-control study.
    Akiyama M; Kaneko Y; Yamaoka K; Kondo H; Takeuchi T
    Rheumatol Int; 2016 Jun; 36(6):881-9. PubMed ID: 27072347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.